/cloudfront-us-east-1.images.arcpublishing.com/tgam/S5XDGWTINBNO5MAX6SZNDNTM7E.jpg)
Nurse Carolyn Grausgruber gives a volunteer an injection as the world's biggest study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway on July 27, 2020, in Binghamton, N.Y.
The Associated Press
Moderna Inc plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the vaccine outside the United States.
Moderna began the U.S. government-backed trial on Monday, among a handful of companies that have started final testing of their experimental vaccines on tens of thousands of healthy volunteers.
Chief Executive Officer Stéphane Bancel declined to comment on the specific price of the vaccine on a conference call with analysts.
“We are highly aware of our obligation during the pandemic phase to be responsible in how we price the vaccine,” Bancel said.
The Financial Times reported on Tuesday, citing unnamed sources, that the company was planning to price the vaccine at $50 to $60 per course, at least $11 more than another vaccine from Pfizer Inc and BioNTech.
Moderna executives also said the enrollment for the late-stage trial was on track and the company had seen tremendous interest from clinical sites.
Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.
/www.theglobeandmail.com/files/dev/uxtest/coronahub/the-zero-canada-project-200x160.png)